Table 1

Baseline characteristics and large B-cell lymphoma risk factors of the 27 patients with rheumatic diseases

Case no	Rheumatic diseases	Sex	Age (years) at LBCL diagnosis	Years from rheumatic disease symptoms to LBCL diagnosis	IPI	Bulk disease	c-MYC rearrangements	LBCL
1	pSS	F	52	32	Low/intermediate	+	−	DLBCL, NOS
2	pSS	F	59	19	Intermediate/high	NA	−	DLBCL, NOS
3	pSS	F	53	18	Low/intermediate	−	−	DLBCL, NOS
4	pSS	F	48	38	Low	NA	−	DLBCL, NOS
5	pSS	F	83	22	Intermediate/high	NA	−	DLBCL, NOS
6	pSS	F	59	13	Low	−	NA	DLBCL
7	pSS	F	47	26	High	−	–	DLBCL
8	pSS	F	51	22	High	NA	−	DLBCL, NOS
9	pSS	F	39	6	High	−	−	DLBCL, NOS
10	pSS	F	62	15	High	NA	NA	DLBCL, NOS
11	pSS	F	45	22	Intermediate/high	+	NA	DLBCL
12	pSS	F	70	18	High	−	NA	DLBCL
13	pSS	F	73	18	High	+	−	DLBCL
14	pSS	F	73	24	Intermediate/high	−	−	DLBCL, NOS
15	pSS	F	67	15	High	+	−	DLBCL, NOS
16	pSS	F	30	3	Low	−	−	DLBCL, NOS
17	pSS	F	61	20	Intermediate/high	−	−	EBV-positive DLBCL, NOS; monomorphic
18	pSS	F	42	21	Low/intermediate	−	NA	EBV-positive DLBCL, NOS; polymorphic
19	pSS	F	43	22	Low	NA	NA	THRLBCL
20	pSS	F	57	14	Intermediate/high	−	NA	THRLBCL
21	SLE and sSS	F	61	25	Low/intermediate	+	−	DLBCL, NOS
22	SLE and APS	F	58	2	Low	+	−	DLBCL, NOS
23	SLE	M	60	5	Intermediate/high	−	−	DLBCL, NOS
24	RA	F	57	22	Intermediate/high	−	−	DLBCL, NOS
25	RA and sSS	F	62	19	High	−	−	DLBCL, NOS
26	SSc and sSS	F	59	26	Low	−	−	DLBCL, NOS
27	SSc and sSS	F	59	0	Low/intermediate	−	NA	DLBCL

+, positive; −, negative; APS, antiphospholipid syndrome; DLBCL, NOS, diffuse large B-cell lymphoma, not otherwise specified; EBV, Epstein-Barr virus; F, female; IPI, International Prognostic Index; LBCL, large B-cell lymphoma; M, male; NA, not available; pSS, primary Sjogren’s syndrome; RA, rheumatoid arthritis; SSc, systemic sclerosis; sSS, secondary Sjogren’s syndrome; THRLBCL, T-cell/histiocyte-rich large B-cell lymphoma.